Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 118 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: OnabotulinumtoxinA (Botox®) Injections Clear all
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

NCT04815967
View directory record Official record
Conditions
Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury, Cervical Spinal Cord Injury, Cerebral Palsy
Interventions
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 3, 2026, 6:19 PM EDT
Enrolling by invitation No phase listed Observational

Migraine Medication Effects on Urinary Symptoms

NCT06212661
View directory record Official record
Conditions
Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
Interventions
Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910520
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 3, 2026, 6:19 PM EDT
Not listed Phase 2Phase 3 Interventional

This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.

NCT00479596
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox
Drug
Lead sponsor
Urological Sciences Research Foundation
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Pediatric Lower Limb Spasticity Follow-on Study

NCT01251380
View directory record Official record
Conditions
Cerebral Palsy, Muscle Spasticity, Children
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 17 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Aurora, Colorado • Chicago, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity

NCT01603615
View directory record Official record
Conditions
Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
2 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Pasadena, California • Pomona, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of OnabotulinumtoxinA (BOTOX®) on Stress

NCT06778421
View directory record Official record
Conditions
Stress (Psychology), Stress, Healthy Adult Female Participants, Stress, Psychologic, Stress, Psychological Cumulative, Stress, Physiological, Stress Response, Stress Levels, Stress Perception
Interventions
Intramuscular injection, OnabotulinumtoxinA (Botox®) Injections, Sodium Chloride
Procedure · Drug · Other
Lead sponsor
Center for Advanced Facial Plastic Surgery
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines

NCT00856414
View directory record Official record
Conditions
Skin Aging
Interventions
botulinum toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 55 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
West Palm Beach, Florida • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 3, 2026, 6:19 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

NCT06034288
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Xeomin 100 UNT Injection, Botox 100 UNT Injection
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

NCT04994535
View directory record Official record
Conditions
Platysma Prominence
Interventions
OnabotulinumtoxinA, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows

NCT00752050
View directory record Official record
Conditions
Glabellar Rhytides, Frown Lines Between the Eyebrows
Interventions
Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910845
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 3, 2026, 6:19 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

NCT04099667
View directory record Official record
Conditions
Spasticity
Interventions
Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.

NCT04936542
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
AboBoNT-A, OnaBoNT-A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 3, 2026, 6:19 PM EDT
Terminated Not applicable Interventional Results available

Botulinum Toxin A for Herpes Labialis

NCT01225341
View directory record Official record
Conditions
Herpes Labialis
Interventions
onabotulinumtoxinA, Bacteriostatic normal saline
Drug · Other
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Botulinum Toxin and Recovery of Hand Function After Stroke

NCT01422161
View directory record Official record
Conditions
Stroke With Hemiparesis
Interventions
Botulinum Toxin commonly known as BOTOX®, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 3, 2026, 6:19 PM EDT
Terminated Not applicable Interventional Results available

A Study of Remote Electrical Neuromodulation for Acute Procedural Pain

NCT05730556
View directory record Official record
Conditions
Chronic Migraine
Interventions
Nerivio ®, Sham
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis

NCT02230956
View directory record Official record
Conditions
Osteoarthritis
Interventions
onabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

NCT00156910
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence

NCT02678377
View directory record Official record
Conditions
Mixed Urinary Incontinence, Stress Urinary Incontinence, Urgency Incontinence
Interventions
OnabotulinumtoxinA (Botox ®) Injections, Saline Injections
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 3, 2026, 6:19 PM EDT
Completed Phase 2 Interventional

Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment

NCT00651690
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Botulinum Toxin Type A, Placebo
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 3, 2026, 6:19 PM EDT
Terminated Phase 2 Interventional Results available

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

NCT00711087
View directory record Official record
Conditions
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions
BOTOX-A, Saline injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 3, 2026, 6:19 PM EDT
Recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713
View directory record Official record
Conditions
Chronic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
48
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 3, 2026, 6:19 PM EDT